Aurisco Pharmaceutical est le premier fabricant mondial d'oligonucléotides génériques à avoir passé avec succès l'inspection de l'USFDA

Aurisco Pharmaceutical a annoncé que son site de Yangzhou (Chine) a passé avec succès l’inspection USFDA préalable à l’autorisation de mise sur le marché pour l’Inclisiran Sodium, menée du 15 au 19 juin 2026. L’évaluation a porté sur la conformité BPF/CGMP pour les oligonucléotides, peptides (GLP-1 incluant sémaglutide et tirzépatide) et petites molécules, avec un EIR confirmant la prise en compte des remarques via un plan CAPA approuvé. L’entreprise se positionne comme premier fabricant mondial de principes actifs génériques à base d’oligonucléotides et indique que cette approbation ouvre la voie à de futurs produits (Inclisiran, Vutrisiran, Nusinersen, Eplontersen, etc.).

Analysis

This is less a near-term revenue event than a credibility event. For Aurisco, FDA validation turns its oligo capability from a regional cost story into a regulated-platform story, which should improve win rates in CDMO RFPs and make it a more credible second-source for Western pharma seeking supply-chain diversification. The first-order equity read-through is positive for 605116.SS; the second-order read-through is a margin reset for any incumbent CDMO charging scarcity rents in complex TIDES manufacturing.

The more interesting market implication is on the eventual pricing power of oligonuclotide franchises. If Aurisco can reliably supply GMP-grade material, the long-term losers are the originators with the largest exposure to future biosimilar/generic-style erosion in RNAi and antisense drugs — names like NVS, ALNY, BIIB, and IONS — but that risk is measured in years, not weeks, because patent, settlement, and commercial-scale hurdles still sit between inspection success and actual generic launches. In the next 1-3 months, the catalyst is not sales but follow-on signals: filings, partner announcements, or more FDA inspections that validate this is repeatable rather than one-off.

Consensus may be overestimating how quickly this converts into cash flow and underestimating how strategic it is as a platform foothold. The bullish case is that a China-based supplier just cleared a barrier that has kept the oligo supply chain concentrated and expensive; that could eventually compress costs across a set of high-margin therapies and improve payer leverage. The bearish case is that this remains optionality until a specific product path clears litigation and commercial substitution, so any front-running in the underlying biotech names is likely premature unless we see an actual generic filing or settlement.

Key Decisions for Investors

• Long 605116.SS on pullbacks over the next 1-2 weeks as a strategic platform optionality trade; use a tight stop if the post-news breakout fails, because the upside is mainly re-rating rather than immediate earnings.
• Do not short ALNY/BIIB/NVS/IONS yet; wait for a concrete filing, settlement, or partner disclosure. If you want exposure, use a 6-12 month watchlist trigger rather than paying theta now.
• Relative-value idea: long 605116.SS / short XBI on a small size if you want to express 'regulated manufacturing moat' versus 'duration-heavy biotech'; thesis fails if the FDA later raises CMC objections or if no repeat inspections follow.
• For CDMO exposure, favor any liquid large-cap supplier with oligo/pharma services leverage over pure R&D biotech for the next 3-6 months, because this news improves outsourced manufacturing demand and diversification budgets more than drug sales.
• Set an alert for the first public generic/ANDA-type filing tied to inclisiran/vutrisiran/nusinersen/eplontersen; that is the real catalyst for a 12-24 month bear case on the originators and the point to revisit short exposure.